ARCT
Arcturus Therapeutics Holdings Inc.
There isn't enough reported data to score ARCT yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
ARCT Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
ARCT's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
ARCT PE Valuation
ARCT has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
ARCT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect ARCT's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
ARCT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.10 | -$0.65 |
| Q2 2026 | -$3.33 | -$1.11 |
| Q1 2026 | -$2.83 | -$0.31 |
| Q4 2025 | -$2.40 | +$0.60 |
| Q3 2025 | -$2.45 | -$0.15 |
| Q2 2025 | -$2.22 | +$0.43 |
| Q1 2025 | -$2.52 | +$1.47 |
| Q4 2024 | -$3.00 | -$1.88 |
ARCT is still losing money, but far less than before: $3.10 per share over the past year, against $7.74 at its worst in late 2021.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over ARCT on earnings quality, reporting a profit while its opponent remains loss making.
ARCT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $18.3M | +6.7% |
| Q2 2026 | $3M | -90% |
| Q1 2026 | $2.1M | -93% |
| Q4 2025 | $7.2M | -68% |
| Q3 2025 | $17.2M | -59% |
| Q2 2025 | $28.3M | -43% |
| Q1 2025 | $29.4M | -23% |
| Q4 2024 | $22.8M | -26% |
ARCT's revenue is recovering but still below its 2022 peak: $18M last quarter, up 6.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -50% | +46 points |
| Q2 2026 | -863% | -822 points |
| Q1 2026 | -1404% | -1347 points |
| Q4 2025 | -435% | -288 points |
| Q3 2025 | -96% | -71 points |
| Q2 2025 | -41% | +1.3 points |
| Q1 2025 | -57% | +23 points |
| Q4 2024 | -147% | -88 points |
ARCT's operating margin was −50% last quarter, up 46 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over ARCT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over ARCT on profitability, with a higher operating margin.
ARCT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$7M | +$10.4M |
| Q2 2026 | -$19.9M | -$14.2M |
| Q1 2026 | -$19.4M | +$15.8M |
| Q4 2025 | -$16.1M | -$15.9M |
| Q3 2025 | -$17.3M | +$6.5M |
| Q2 2025 | -$5.8M | +$24.7M |
| Q1 2025 | -$35.3M | -$29.5M |
| Q4 2024 | -$284K | +$1.2M |
ARCT has burned cash in almost every quarter: −$62M over the past year, against −$59M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over ARCT on cash generation, producing positive trailing cash flow while its opponent burns cash.
ARCT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +17K shares |
| 1 year | +4.6% | +1.3M shares |
| 3 years | +5% | +1.3M shares |
| 5 years | +14% | +3.6M shares |
ARCT has 28M diluted shares, up 4.6% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over ARCT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
ARCT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2023 | -4.6x | Net Cash |
| Q4 2022 | -24.1x | Net Cash |
ARCT has more cash than debt.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
ARCT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.7 | Neutral |
| Stochastic | 31.9 | Neutral |
ARCT's weekly RSI is 44 (neutral) and its Stochastic is 32 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
ARCT PE vs Healthcare Sector
| Metric | ARCT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ARCT has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
ARCT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.3 | 26% below |
| 20 week MA | $10.7 | 21% below |
| 50 week MA | $8.73 | 3.3% below |
| 100 week MA | $11.6 | 27% below |
| 200 week MA | $18.8 | 55% below |
ARCT is in a downtrend: it's below all five of its weekly moving averages, and 55% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over ARCT on trend strength, trading above more of its moving averages.
ARCT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $11.5 | $98.1 | +756% |
| 2021 | $98.1 | $39.9 | -59% |
| 2022 | $39.9 | $17.3 | -57% |
| 2023 | $17.3 | $31.5 | +83% |
| 2024 | $31.5 | $17.0 | -46% |
| 2025 | $17.0 | $6.16 | -64% |
| 2026 YTD | $6.16 | $8.44 | +37% |
ARCT has the edge over UNH on returns for 2026, with the stronger performance.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has finished three years in a row lower, and it's up 22% so far in 2026.